CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Rivaroxaban-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism after total knee replacement: Results of a randomized multi-center trial
The Journal of Arthroplasty, ISSN: 0883-5403, Vol: 24, Issue: 2, Page: e40
Knee
Link to article
Rivaroxaban-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism after total knee replacement: Results of a randomized multi-center trial
Jay R. Lieberman; Nadia Rosencher; Frank MisselwitzKnee
Rivaroxaban-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism after total knee replacement: Results of a randomized multi-center trial
Link to article